Chemokine/Chemokine Receptor Nomenclature

As a service to our authors and readers, the journal is publishing this updated nomenclature table associated with chemokines.

Chemokine/Chemokine Receptor Nomenclature* International Union of Immunological Societies/World Health Organization Subcommittee on Chemokine Nomenclature1 The chemokines comprise a large protein family that can be divided into sub-families on the basis of structural motifs. The common property of chemokines is leukocyte chemotaxis. Until recently, chemokines have been named randomly with no clear system being used. Some have been included with the interleukins (e.g., IL-8), others given names describing a function, e.g., macrophage chemotactic proteins. Others have been named according to the cell type that produces the chemokine, e.g., platelet factor 4, whereas others have been named arbitrarily. In some cases the names that have been chosen are cumbersome to use which has resulted in these chemokines being almost always referenced by an abbreviated form of the name e.g., RANTES. Many chemokines show overlapping functions. This has caused some confusion in identifying the molecules associated with particular experimental observations. Chemokines mediate their biological effects via interactions with a large family of 7-transmembrane G protein-coupled receptors. Although each receptor subtype typically binds multiple chemokines, the specificity is restricted by chemokine subfamily. This has led to a logical receptor nomenclature system in which each receptor is designated by chemokine subfamily name (C, CC, CXC, CX3C) followed by the letter “R” (for “receptor”) and a number based on the chronological order in which it was identified. This system has been in place since 1996 and has been officially endorsed by the Nomenclature Committee of the International Union of Pharmacology (Pharmacological Reviews, 2000, 52, 145–176). In some cases (see below) CD numbers have been assigned to particular chemokine receptors, and the block CD181-CD199 has been reserved for future use for such receptors. In an attempt to clarify if not solve the now confused and complex nomenclature associated with chemokines, Drs. Osamu Yoshie and Albert Zlotnik have devised a systematic nomenclature paralleling that of the receptor nomenclature system that was recently published (Immunity, 2000, 12, 121–127). The Chemokine Nomenclature Subcommittee of the Nomenclature Committee of the International Union of Immunological Societies has considered this system and recommended its adoption by IUIS/WHO. The system is outlined in the following table. Those scientists wishing to maintain a linkage with the historical nomenclature are recommended to quote this in brackets after the systematic name. The following table is an updated version of the system.

* This report has been approved by the IUIS/WHO Nomenclature Committee. 1 Antal Rot (Austria) Kevin Bacon (Japan) Thomas Schall (USA) Marco Baggiolini (Switzerland) Monica Tsang (USA) Hal Broxmeyer (USA) Robin Thorpe (Chairman) (UK) Richard Horuk (USA) Jo Van Damme (Belgium) Ivan Lindley (Austria) Meenu Wadhwa (UK) Alberto Mantovani (Italy) Osamu Yoshie (Japan) Kouji Matsushima (Japan) Albert Zlotnik (USA) Philip Murphy (USA) Kathy Zoon (USA) Hisayuki Nomiyama (Japan) Joost Oppenheim (USA)

Journal of Leukocyte Biology Volume 70, September 2001

465

CXC, C, CX3C and CC Chemokine/Receptor Families Systematic name

Human chromosome

Human ligand

Mouse ligand

Chemokine receptor(s)

CXC chemokine-receptor family CXCL1 CXCL2 CXCL3 CXCL4 CXCL5 CXCL6 CXCL7 CXCL8 CXCL9 CXCL10 CXCL11 CXCL12 CXCL13 CXCL14 (CXCL15) CXCL16

4q21.1 4q21.1 4q21.1 4q21.1 4q21.1 4q21.1 4q21.1 4q21.1 4q21.1 4q21.1 4q21.1 10q11.21 4q21.1 5q31.1

GRO␣/MGSA-␣ GRO␤/MGSA-␤ GRO␥/MGSA-␥ PF4 ENA-78 GCP-2 NAP-2 IL-8 Mig IP-10 I-TAC SDF-1 ␣/␤ BCA-1 BRAK/bolekine Unknown

GRO/MIP-2/KC? GRO/MIP-2/KC? GRO/MIP-2/KC? PF4 GCP-2/LIX? GCP-2/LIX? Unknown Unknown Mig IP-10/CRG-2 I-TAC SDF-1/PBSF BLC BRAK Lungkine/WECHE

CXCR2 ⬎ CXCR1 CXCR2 CXCR2 Unknown CXCR2 CXCR1, CXCR2 CXCR2 CXCR1, CXCR2 CXCR3a CXCR3a CXCR3a CXCR4b CXCR5 Unknown Unknown CXCR6

Lymphotactin/SCM-1␣/ATAC SCM-1␤

Lymphotactin Unknown

XCR1 XCR1

Fractalkine

Neurotactin/ABCD-3

CX3CR1

I-309 MCP-1/MCAF/TDCF MIP-1␣/LD78␣ LD78␤ MIP-1␤ RANTES Unknown MCP-3 MCP-2 Unknown Eotaxin Unknown MCP-4 HCC-1 HCC-2/Lkn-1/MIP-1␦ HCC-4/LEC/LCC-1 TARC DC-CK1/PARC/AMAC-1 MIP-3␤/ELC/exodus-3 MIP-3␣/LARC/exodus-1 6Ckine/SLC/exodus-2 MDC/STCP-1 MPIF-1/CK␤8/CK␤8-1 Eotaxin-2/MPIF-2 TECK Eotaxin-3 CTACK/ILC MEC

TCA-3/P500 JE? MIP-1␣ Unknown MIP-1␤ RANTES C10/MRP-1 MARC? MCP-2? MRP-2/CCF18/MIP-1␥ Eotaxin MCP-5 Unknown Unknown Unknown Unknown TARC/ABCD-2 Unknown MIP-3␤/ELC/exodus-3 MIP-3␣/LARC/exodus-1 6Ckine/SLC/exodus-2/TCA-4 ABCD-1 Unknown MPIF-2 TECK Unknown ALP/CTACK/ILC/ESkine

CCR8 CCR2 CCR1, CCR5 CCR1, CCR5 CCR5c CCR1, CCR3, CCR5c Unknown CCR1, CCR2, CCR3 CCR3, CCR5c CCR1 CCR3 CCR2 CCR2, CCR3 CCR1, CCR5 CCR1, CCR3 CCR1, CCR2 CCR4 Unknown CCR7d CCR6 CCR7d CCR4 CCR1 CCR3 CCR9 CCR3 CCR10 CCR3/CCR10

17p13

C chemokine/receptor family XCL1 XCL2

1q24.2 1q24.2

CX3C chemokine/receptor family CX3CL1

16q13

CC chemokine/receptor family CCL1 CCL2 CCL3 CCL3L1 CCL4 CCL5 (CCL6) CCL7 CCL8 (CCL9/10) CCL11 (CCL12) CCL13 CCL14 CCL15 CCL16 CCL17 CCL18 CCL19 CCL20 CCL21 CCL22 CCL23 CCL24 CCL25 CCL26 CCL27 CCL28 a

CD183.

17q11.2 17q11.2 17q12 17q12 17q12 17q12 17q11.2 17q11.2 17q11.2 17q11.2 17q12 17q12 17q12 16q13 17q12 9p13.3 2q36.3 9p13.3 16q13 17q12 7q11.23 19p13.3 7q11.23 9p13.3 5p12 b

CD184.

c

CD195.

d

CDw 197.

Erratum Beauvois, B. Transmembrane proteases in focus: diversity or redundancy? J. Leukoc. Biol. (2001) 70: 11-17 On page 13 of this article under the heading, The ADAMS, the following line should read: For example, ADAM-15, expressed in a wide variety of cells including human leukocytes, exhibits RGD [8], and ADAM-2 and ADAM-9 contain an ECD (Glu-Cys-Asp) motif [40-42]. The editors regret any inconvenience this error might have caused. 466

Journal of Leukocyte Biology Volume 70, September 2001

http://www.jleukbio.org